====== MCT1 ======

High Expression in GBM:

MCT1 and [[MCT4]] are significantly overexpressed in IDH-wildtype [[glioblastoma]]s compared to IDH-mutant gliomas (grades 2–4), both at the [[protein]] (IHC) and [[mRNA]] levels.

Endothelial Proliferation Specificity:

Loss of MCT1 expression was noted in areas of endothelial proliferation within grade 4 gliomas, contrasting with its presence in non-proliferating endothelium—suggesting a specific microenvironmental regulation.

Prognostic Implications:

High MCT1/4 expression correlates with shorter overall survival when analyzing all [[glioma]]s together, although this correlation was not significant in GBM alone.

Therapeutic Insight – [[Syrosingopine]]:

Syrosingopine, a dual MCT1/4 inhibitor and old antihypertensive drug with good CNS penetration, showed dose-dependent anti-tumor effects in vitro on U87MG and LN229 glioma cell lines:

Increased cytotoxicity

Enhanced apoptosis

Reduced migration/invasion

Clinical Relevance:

MCT1/4 may serve as diagnostic immunohistochemical markers.

[[Syrosingopine]], a dual [[MCT1]]/4 inhibitor and old antihypertensive drug with good CNS penetration, showed dose-dependent anti-tumor effects in vitro on [[U87]]MG and [[LN229]] glioma cell lines:

Increased cytotoxicity

Enhanced apoptosis

Reduced migration/invasion

Clinical Relevance:

MCT1/4 may serve as diagnostic immunohistochemical markers.

Syrosingopine may represent a promising adjunctive therapy for GBM
((Behera MM, Purkait S, Ghosh A, Sable MN, Sahu RN, Chhabra G. The [[Monocarboxylate Transporter]]s [[MCT1]] and [[MCT4]] Are Highly Expressed in [[Glioblastoma]] and Crucially Implicated in the [[Pathobiology]]. Neuropathology. 2025 Mar 27. doi: 10.1111/neup.70006. Epub ahead of print. PMID: 40145253.))